anti-lymphocyte globulin
Biologicalexperimental
Anti-lymphocyte globulin (ALG) is an infusion of animal- antibodies against human T cells which is used in the treatment of acute rejection in organ transplantation. Its use was first reported by Thomas Starzl in 1966. Its use in transplant was supplanted by thymoglobulin between 1984 and 1999. — Wikipedia
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started May 1, 2004 (NCT02461121)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 3 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetImmunity, passive
immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAnti-lymphocyte globulin ↗
Also known as
- anti-lymphocyte globulin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06525519 | Phase 3 | Jul 31, 2024 | China Academy of Chinese Medical Sciences |
| NCT02461121 | Phase 3 | May 1, 2004 | People's Liberation Army of China |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| China Academy of Chinese Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2024 |
| People's Liberation Army of China | Government | 1 | 1 | 1 | 2004 |
2 organizations
Page 1 / 1